Dealing with the uncertain risk of variant Creutzfeldt-Jakob disease transmission by coagulation replacement products

British Journal of Haematology

Volumn 158, Issue 4, 2012, Pages 442-452

  Millar, Carolyn M ^a   Makris, Mike ^b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b Sheffield Haemophilia and Thrombosis Centre ^*  (United Kingdom)

Author keywords

Coagulation factor; Haemophilia; Plasma; Risk; Variant Creutzfeldt Jakob disease

Indexed keywords

BLOOD CLOTTING FACTOR CONCENTRATE; FRESH FROZEN PLASMA; PRION PROTEIN; RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 9;

AGE; ANTICOAGULANT THERAPY; BLEEDING DISORDER; BLOOD TRANSFUSION; CRYOPRECIPITATION; DISEASE TRANSMISSION; GENE; GENETIC VARIABILITY; GENOTYPE; GEOGRAPHIC DISTRIBUTION; HEALTH CARE POLICY; HEMOPHILIA A; HEMOPHILIA B; HETEROZYGOSITY; HUMAN; IMMUNOASSAY; MORTALITY; NONHUMAN; POSTMARKETING SURVEILLANCE; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; PRNP GENE; PUBLIC HEALTH; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SCREENING TEST; SENSITIVITY AND SPECIFICITY; UNITED KINGDOM; VARIANT CREUTZFELDT JAKOB DISEASE;

BLOOD COAGULATION DISORDERS, INHERITED; BLOOD COAGULATION FACTORS; BLOOD TRANSFUSION; CREUTZFELDT-JAKOB SYNDROME; HUMANS; MALE; MASS SCREENING; POPULATION SURVEILLANCE; PREVALENCE; RECOMBINANT PROTEINS; RISK ASSESSMENT;

EID: 84864294891     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2012.09201.x     Document Type: Review

References (63)

1. ACDP (2011a) Assessment to be carried out before surgery and/or endoscopy to identify patients with, or at increased risk of, CJD or vCJD. accessed March 2012
2. ACDP (2011b) Part 4 Infection control of CJD, vCJD and other human prion diseases in healthcare and community settings. accessed March 2012
3. ACDP (2011c) Annexe F Endosopy. accessed March 2012
4. AFSSAPS (2003) Analysis of the Risk of Variant Creutzfeldt-Jakob Disease Transmssion by Medicinal Products of Human Origin and Labile Blood Products. Agence française de sécurité sanitaire des produits de santé, Paris. accessed March 2012
5. Bishop, M.T., Hart, P., Aitchison, L., Baybutt, H.N., Plinston, C., Thomson, V., Tuzi, N.L., Head, M.W., Ironside, J.W., Will, R.G. & Manson, J.C. (2006) Predicting susceptibility and incubation time of human-to-human transmission of vCJD. Lancet Neurology, 5, 393-398.
6. Boelle, P.Y., Cesbron, J.Y. & Valleron, A.J. (2004) Epidemiological evidence of higher susceptibility to vCJD in the young. BioMedCentral Infectious Diseases, 4, 26.
7. Brown, P. (2000) BSE and transmission through blood. Lancet, 356, 955-956.
8. Brown, P., Rohwer, R.G., Dunstan, B.C., MacAuley, C., Gajdusek, D.C. & Drohan, W.N. (1998) The distribution of infectivity in blood components and plasma derivatives in experimental models of transmissible spongiform encephalopathy. Transfusion, 38, 810-816.
9. Brown, P., Cervenáková, L., McShane, L.M., Barber, P., Rubenstein, R. & Drohan, W.N. (1999) Further studies of blood infectivity in an experimental model of transmissible spongiform encephalopathy, with an explanation of why blood components do not transmit Creutzfeldt-Jakob disease in humans. Transfusion, 39, 1169-1178.
10. Brown, K.L., Wathne, G.J., Sales, J., Bruce, M.E. & Mabbott, N.A. (2009) The effects of host age on follicular dendritic cell status dramatically impair scrapie agent neuroinvasion in aged mice. Journal of Immunology, 183, 5199-5207.
11. Bruce, M.E., Will, R.G., Ironside, J.W., McConnell, I., Drummond, D., Suttie, A., McCardle, L., Chree, A., Hope, J., Birkett, C., Cousens, S., Fraser, H. & Bostock, C.J. (1997) Transmissions to mice indicate that 'new variant' CJD is caused by the BSE agent. Nature, 389, 498-501.
12. CJDIP (2004a) Management of possible exposure to CJD through medical procedures. accessed March 2012
13. CJDIP (2004b) Assessment of exposure to particular batches of variant Creutzfeldt-Jakob disease (vCJD) implicated plasma products. > accessed March 2012
14. Clarke, P. & Ghani, A.C. (2005) Projections of the future course of the primary vCJD epidemic in the UK: inclusion of subclinical infection and the possibility of wider genetic susceptibility. Journal of the Royal Society, Interface, 2, 19-31.
15. Clewley, J.P., Kelly, C.M., Andrews, N., Vogliqi, K., Mallinson, G., Kaisar, M., Hilton, D.A., Ironside, J.W., Edwards, P., McCardle, L.M., Ritchie, D.L., Dabaghian, R., Ambrose, H.E. & Gill, O.N. (2009) Prevalence of disease related prion protein in anonymous tonsil specimens in Britain: cross sectional opportunistic survey. BMJ, 338, b1442.
16. Collinge, J. (2001) Prion diseases of humans and animals: their causes and molecular basis. Annual Review of Neuroscience, 24, 519-550.
17. Collinge, J., Whitfield, J., McKintosh, E., Beck, J., Mead, S., Thomas, D.J. & Alpers, M.P. (2006) Kuru in the 21st century-an acquired human prion disease with very long incubation periods. Lancet, 367, 2068-2074.
18. Comer, P. & Spouge, J. (1999) Assessment of the risk of exposure to vCJD infectivity in blood and blood products. Det Norske Veritas Final Report, Job No. 8288. Det Norske Veritas, London, UK.
19. Cousens, S.N., Vynnycky, E., Zeidler, M., Will, R.G. & Smith, P.G. (1997) Predicting the CJD epidemic in humans. Nature, 385, 197-198.
20. CPMP (1998) Position statement on new variant CJD and plasma-derived medicinal products. European Agency for the Evaluation of Medicinal Products, London.
21. DH (2001) Risk assessment for transmission of vCJD via Surgical Instruments: A modelling approach and numerical scenarios. Department of Health, UK.
22. DNV (2003). Risk Assessment of Exposure to vCJD Infectivity in Blood and Blood Products. Report for UK Department of Health. Det Norske Veritas Report no. 716108 Rev D (Final) 24 February 2003. Det Norske Veritas, London, UK.
23. Edgeworth, J.A., Jackson, G.S., Clarke, A.R., Weissmann, C. & Collinge, J. (2009) Highly sensitive, quantitative cell-based assay for prions adsorbed to solid surfaces. Proceedings of the National Academy of Sciences of the United States of America, 106, 3479-3483.
24. Edgeworth, J.A., Farmer, M., Sicilia, A., Tavares, P., Beck, J., Campbell, T., Lowe, J., Mead, S., Rudge, P., Collinge, J. & Jackson, G.S. (2011) Detection of prion infection in variant Creutzfeldt-Jakob disease: a blood-based assay. Lancet, 377, 487-493.
25. FDA (2006) Draft quantitative risk assessment of vCJD risk potentially associated with the use of human plasma-derived factor VIII manufactured under United States license from plasma collected in the US. http:/. US Food and Drug Administration, Center for Biologics Evaluation and Research. accessed March 2012
26. Foster, P.R. (1999) Assessment of the potential of plasma fractionation processes to remove causative agents of transmissible spongiform encephalopathy. Transfusion Medicine (Oxford, England), 9, 3-14.
27. Foster, P.R., Welch, A.G., McLean, C., Griffin, B.D., Hardy, J.C., Bartley, A., MacDonald, S. & Bailey, A.C. (2000) Studies on the removal of abnormal prion protein by processes used in the manufacture of human plasma products. Vox Sanguinis, 78, 86-95.
28. Foster, P.R., Griffin, B.D., Bienek, C., McIntosh, R.V., MacGregor, I.R., Somerville, R.A., Steele, P.J. & Reichl, H.E. (2004) Distribution of a bovine spongiform encephalopathy-derived agent over ion-exchange chromatography used in the preparation of concentrates of fibrinogen and factor VIII. Vox Sanguinis, 86, 92-99.
29. Garske, T. & Ghani, A.C. (2010) Uncertainty in the Tail of the variant Creutzfledt Jakob disease epidemic in the UK. PLoS ONE, 5, e15626.
30. Ghani, A.C., Ferguson, N.M., Donnelly, C.A., Hagenaars, T.J. & Anderson, R.M. (1998) Estimation of the number of people incubating variant CJD. Lancet, 352, 1353-1354.
31. Ghani, A.C., Donnelly, C.A., Ferguson, N.M. & Anderson, R.M. (2003) Updated projections of future vCJD deaths in the UK. BioMedCentral Infectious Diseases, 3, 4.
32. Head, M.W., Ritchie, D., Smith, N., McLoughlin, V., Nailon, W., Samad, S., Masson, S., Bishop, M., McCardle, L. & Ironside, J.W. (2004) Peripheral tissue involvement in sporadic, iatrogenic, and variant Creutzfeldt-Jakob disease: an immunohistochemical, quantitative, and biochemical study. American Journal of Pathology, 164, 143-153.
33. Hewitt, P.E., Llewelyn, C.A., Mackenzie, J. & Will, R.G. (2006) Creutzfeldt-Jakob disease and blood transfusion: results of the UK Transfusion Medicine Epidemiological Review Study. Vox Sanguinis, 91, 221-230.
34. Hill, A.F., Joiner, S., Linehan, J., Desbruslais, M., Lantos, P.L. & Collinge, J. (2000) Species-barrier-independent prion replication in apparently resistant species. Proceedings of the National Academy of Sciences of the United States of America, 97, 10248-10253.
35. Hilton, D.A., Ghani, A.C., Conyers, L., Edwards, P., McCardle, L., Ritchie, D., Penney, M., Hegazy, D. & Ironside, J.W. (2004) Prevalence of lymphoreticular prion protein accumulation in UK tissue samples. Journal of Pathology, 203, 733-739.
36. Holada, K., Vostal, J.G., Theisen, P.W., MacAuley, C., Gregori, L. & Rohwer, R.G. (2002) Scrapie infectivity in hamster blood is not associated with platelets. Journal of Virology, 76, 4649-4650.
37. Houston, F., Foster, J.D., Chong, A., Hunter, N. & Bostock, C.J. (2000) Transmission of BSE by blood transfusion in sheep. Lancet, 356, 999-1000.
38. HPA (2006) New case of transfusion-associated variant CJD. The Communicable Disease Report Weekly, 16(16), 11.
39. HPA (2011) Health Protection Report., United Kingdom.
40. Hunter, N., Foster, J., Chong, A., McCutcheon, S., Parnham, D., Eaton, S., MacKenzie, C. & Houston, F. (2002) Transmission of prion diseases by blood transfusion. Journal of General Virology, 83, 2897-2905.
41. Kaski, D., Mead, S., Hyare, H., Cooper, S., Jampana, R., Overell, J., Knight, R. & Collinge, J. (2009) Variant CJD in an individual heterozygous for PRNP codon 129. The Lancet, 374, 2128.
42. Llewelyn, C.A., Hewitt, P.E., Knight, R.S., Amar, K., Cousens, S., Mackenzie, J. & Will, R.G. (2004) Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. Lancet, 363, 417-421.
43. McGowan, C.R. & Viens, A.M. (2011) Coroners and the obligation to protect public health: the case of the failed UK vCJD study. Public Health, 125, 234-237.
44. Millar, C.M., Connor, N., Dolan, G., Lee, C.A., Makris, M., Wilde, J., Winter, M., Ironside, J.W., Gill, N. & Hill, F.G. (2010) Risk reduction strategies for variant Creutzfeldt-Jakob disease transmission by UK plasma products and their impact on patients with inherited bleeding disorders. Haemophilia, 16, 305-315.
45. NCJDSU (2012) CJD Statistics. The National Creutzfeldt-Jakob Disease Surveillance Unit, Edinburgh. accessed March 2012
46. Pastrana, M.A., Sajnani, G., Onisko, B., Castilla, J., Morales, R., Soto, C. & Requena, J.R. (2006) Isolation and characterization of a proteinase K-sensitive PrPSc fraction. Biochemistry, 45, 15710-15717.
47. Peden, A.H., Head, M.W., Ritchie, D.L., Bell, J.E. & Ironside, J.W. (2004) Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient. Lancet, 364, 527-529.
48. Peden, A., McCardle, L., Head, M.W., Love, S., Ward, H.J., Cousens, S.N., Keeling, D.M., Millar, C.M., Hill, F.G. & Ironside, J.W. (2010) Variant CJD infection in the spleen of a neurologically asymptomatic UK adult patient with haemophilia. Haemophilia, 16, 296-304.
49. Reichl, H.E., Foster P.R ., Welch.A.G., Li Q ., Mac.Gregor.I.R., Somerville R.A ., Fernie.K. & Steele P.J, Taylor.D.M. (2002) Studies on the removal of a bovine spongiform encephalopathy-derived agent by processes used in the manufacture of human immunoglobulin. Vox Sanguinis, 83, 137-145.
50. Scott, M.R., Will, R., Ironside, J., Nguyen, H.O., Tremblay, P., DeArmond, S.J. & Prusiner, S.B. (1999) Compelling transgenetic evidence for transmission of bovine spongiform encephalopathy prions to humans. Proceedings of the National Academy of Sciences of the United States of America, 96, 15137-15142.
51. SEAC (2006a) SEAC Epidemiology Subgroup position statement on the vCJD epidemic. Spongiform Encephalopathy Advisory Committee, London.
52. SEAC (2006b) Position statement on TSE infectivity in blood. Vol. 2006. accessed May 2012
53. Silveira, J.R., Raymond, G.J., Hughson, A.G., Race, R.E., Sim, V.L., Hayes, S.F. & Caughey, B. (2005) The most infectious prion protein particles. Nature, 437, 257-261.
54. St Rose, S.G., Hunter, N., Matthews, L., Foster, J.D., Chase-Topping, M.E., Kruuk, L.E., Shaw, D.J., Rhind, S.M., Will, R.G. & Woolhouse, M.E. (2006) Comparative evidence for a link between Peyer's patch development and susceptibility to transmissible spongiform encephalopathies. BMC Infectious Diseases, 6, 5.
55. Swerdlow, A.J., Higgins, C.D., Adlard, P., Jones, M.E. & Preece, M.A. (2003) Creutzfeldt-Jakob disease in United Kingdom patients treated with human pituitary growth hormone. Neurology, 61, 783-791.
56. Truchot, L., Arnaud, T., Bloy, C. & Perret-Liaudet, A. (2006) CJD PrPsc removal by nanofiltration process: application to a therapeutic immunoglobulin solution (Lymphoglobuline). Biologicals, 34, 227-231.
57. UKHCDO (1997) Guidelines on therapeutic products to treat haemophilia and other hereditary coagulation disorders. Haemophilia, 3, 63-77.
58. Wadsworth, J.D., Joiner, S., Hill, A.F., Campbell, T.A., Desbruslais, M., Luthert, P.J. & Collinge, J. (2001) Tissue distribution of protease resistant prion protein in variant Creutzfeldt-Jakob disease using a highly sensitive immunoblotting assay. Lancet, 358, 171-180.
59. Wadsworth, J.D., Joiner, S., Linehan, J.M., Asante, E.A., Brandner, S. & Collinge, J. (2008) Review. The origin of the prion agent of kuru: molecular and biological strain typing. Philosophical Transactions of the Royal Society of London. Series B: Biological Sciences, 363, 3747-3753.
60. Will, R.G., Ironside, J.W., Zeidler, M., Cousens, S.N., Estibeiro, K., Alperovitch, A., Poser, S., Pocchiari, M., Hofman, A. & Smith, P.G. (1996) A new variant of Creutzfeldt-Jakob disease in the UK. Lancet, 347, 921-925.
61. Wroe, S.J., Pal, S., Siddique, D., Hyare, H., Macfarlane, R., Joiner, S., Linehan, J.M., Brandner, S., Wadsworth, J.D., Hewitt, P. & Collinge, J. (2006) Clinical presentation and pre-mortem diagnosis of variant Creutzfeldt-Jakob disease associated with blood transfusion: a case report. Lancet, 368, 2061-2067.
62. Zaman, S.M., Hill, F.G., Palmer, B., Millar, C.M., Bone, A., Molesworth, A.M., Connor, N., Lee, C.A., Dolan, G., Wilde, J.T., Gill, O.N. & Makris, M. (2011) The risk of variant Creutzfeldt-Jakob disease among UK patients with bleeding disorders, known to have received potentially contaminated plasma products. Haemophilia, 17, 931-937.
63. Zobeley, E., Flechsig, E., Cozzio, A., Enari, M. & Weissmann, C. (1999) Infectivity of scrapie prions bound to a stainless steel surface. Molecular Medicine, 5, 240-243.